Permeabilities of rebamipide via rat intestinal membranes and its colon specific delivery using chitosan capsule as a carrier  

作　　者：Bei-Bei Huang Guo-Feng Li Jing-Hui Luo Lian Duan Kishimoto Nobuaki Yamamoto Akira 

机构地区：[1]Department of pharmacy, Nanfang Hospital, Southern Medical University, Guangzhou 510515, Guangdong Province, China [2]Department of Biopharmaceutics, Kyoto Pharmaceutical University, Misasagi, Yamashinaku, Kyoto 6078414, Japan

出　　处：《World Journal of Gastroenterology》2008年第31期4928-4937,共10页世界胃肠病学杂志（英文版）

基　　金：Research Funding of Medical Association of Japanese-Chinese, Japan

摘　　要：AIM: To investigate the permeability characteristics of rebamipide across intestinal mucosa, and examine the effects of some absorption enhancers on the permeability across the colonic tissue. Another purpose is to demonstrate the colon-specific delivery of rebamipide with or without absorption enhancers using chitosan capsule as a carrier. METHODS: The permeability of rebamipide was evaluated using an in vitro diffusion chamber system, and the effects of some absorption enhancers on the permeability via colon were further investigated. The release of rebamipide from chitosan or gelatin capsule was studied by Japan Pharmacopoeia rotating basket method. The colonic and plasma concentrations were analyzed by high performance liquid chromatography (HPLC) to evaluate colon-targeting action after oral administration of various dosage forms, and rebamipide with absorption enhancers in chitosan dosage forms. RESULTS: The permeability of rebamipide across the jejunal or ileal membranes was higher than the colonic membranes. Both sodium laurate (C12) and labrasol signifi cantly increased permeability across the colon membranes. On the other hand, the release of rebamipide from chitosan capsule was less than 10%totally within 6 h. The area under concentration-time profile of drug in the colon mucosa using chitosan capsules (AUCLI, 1 6011.2 ng·h/g) was 2.5 times and 4.4 times greater than using gelatin capsules and CMC suspension, respectively. Meanwhile, the area under concentration-time profile of drug in the plasma (AUCPL) was 1016.0 ng·h/mL for chitosan capsule, 1887.9 ng·h/mL for CMC suspension p and 2163.5 ng·h/mL for gelatin capsule. Overall, both AUCLI and AUCPL were increased when C12 was co-administrated, but the increase of AUCLI was much greater; the drug delivery index (DDI) was more than 1 compared with simple chitosan capsule group. CONCLUSION: There was a regional difference in the permeability of Rabamipide across the jejunum, ileum and the colon, and passive diffusion seems to be one of the major transAIM： To investigate the permeability characteristics of rebamipide across intestinal mucosa, and examine the effects of some absorption enhancers on the permeability across the colonic tissue. Another purpose is to demonstrate the colon-specific delivery of rebamipide with or without absorption enhancers using chitosan capsule as a carrier. METHODS： The permeability of rebamipide was evaluated using an in vitro diffusion chamber system, and the effects of some absorption enhancers on the permeability via colon were further investigated. The release of rebamipide from chitosan or gelatin capsule was studied by Japan Pharmacopoeia rotating basket method. The colonic and plasma concentrations were analyzed by high performance liquid chromatography （HPLC） to evaluate colon-targeting action after oral administration of various dosage forms, and rebamipide with absorption enhancers in chitosan dosage forms. RESULTS： The permeability of rebamipide across the jejunal or ileal membranes was higher than the colonic membranes. Both sodium laurate （C12） and labrasol significantly increased permeability across the colon membranes. On the other hand, the release of rebamipide from chitosan capsule was less than 10% totally within 6 h. The area under concentration-time profile of drug in the colon mucosa using chitosan capsules （AUCLI, 16011.2 ng.h/g） was 2.5 times and 4.4 times greater than using gelatin capsules and CMC suspension, respectively. Meanwhile, the area under concentration-time profile of drug in the plasma （AUCPL） was 1016.0 ng.h/mL for chitosan capsule, 1887.9 ng.h/mL for CMC suspension p and 2163.5 ng.h/mL for gelatin capsule. Overall, both AUCLI and AUCPL were increased when C12 was coadministrated, but the increase of AUCLI was much greater; the drug delivery index （DDI） was more than 1 compared with simple chitosan capsule group. CONCLUSION： There was a regional difference in the permeability of Rabamipide across the jejunum, ileum and the colon, and passive diffusion seems to be

关 键 词：REBAMIPIDE Diffusion chamber PERMEABILITY Sodium laurate Chitosan capsule Colon-specific delivery 

分 类 号：R97[医药卫生—药品]